239 related articles for article (PubMed ID: 25608485)
1. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
[TBL] [Abstract][Full Text] [Related]
2. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
[TBL] [Abstract][Full Text] [Related]
3. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas.
Ellingson BM; Zaw T; Cloughesy TF; Naeini KM; Lalezari S; Mong S; Lai A; Nghiemphu PL; Pope WB
J Magn Reson Imaging; 2012 Jun; 35(6):1472-7. PubMed ID: 22281731
[TBL] [Abstract][Full Text] [Related]
4. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
[TBL] [Abstract][Full Text] [Related]
5. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
[TBL] [Abstract][Full Text] [Related]
6. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
7. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
8. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
9. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.
Schmainda KM; Prah M; Connelly J; Rand SD; Hoffman RG; Mueller W; Malkin MG
Neuro Oncol; 2014 Jun; 16(6):880-8. PubMed ID: 24431219
[TBL] [Abstract][Full Text] [Related]
10. Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.
Andre JB; Nagpal S; Hippe DS; Ravanpay AC; Schmiedeskamp H; Bammer R; Palagallo GJ; Recht L; Zaharchuk G
Neuroradiol J; 2015 Apr; 28(2):112-9. PubMed ID: 25923677
[TBL] [Abstract][Full Text] [Related]
11. Wavelet-based reconstruction of dynamic susceptibility MR-perfusion: a new method to visualize hypervascular brain tumors.
Huber T; Rotkopf L; Wiestler B; Kunz WG; Bette S; Gempt J; Preibisch C; Ricke J; Zimmer C; Kirschke JS; Sommer WH; Thierfelder KM
Eur Radiol; 2019 May; 29(5):2669-2676. PubMed ID: 30552476
[TBL] [Abstract][Full Text] [Related]
12. Texture Feature Ratios from Relative CBV Maps of Perfusion MRI Are Associated with Patient Survival in Glioblastoma.
Lee J; Jain R; Khalil K; Griffith B; Bosca R; Rao G; Rao A
AJNR Am J Neuroradiol; 2016 Jan; 37(1):37-43. PubMed ID: 26471746
[TBL] [Abstract][Full Text] [Related]
13. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
[TBL] [Abstract][Full Text] [Related]
14. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
15. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
[TBL] [Abstract][Full Text] [Related]
16. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
17. Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI.
Artzi M; Liberman G; Nadav G; Vitinshtein F; Blumenthal DT; Bokstein F; Aizenstein O; Ben Bashat D
Neuroradiology; 2015 Jul; 57(7):671-8. PubMed ID: 25845809
[TBL] [Abstract][Full Text] [Related]
18. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
[TBL] [Abstract][Full Text] [Related]
19. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.
Vidiri A; Pace A; Fabi A; Maschio M; Latagliata GM; Anelli V; Piludu F; Carapella CM; Giovinazzo G; Marzi S
J Exp Clin Cancer Res; 2012 Apr; 31(1):33. PubMed ID: 22494770
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]